Announcement of The Consolidated Financial Report for The 4th Quarter of 2022
2023.3.14
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 3 | Date of announcement | 2023/03/14 | Time of announcement | 19:51:08 |
| Subject | Announcement of The Consolidated Financial Report for The 4th Quarter of 2022 | ||||
| Date of events | 2022/03/14 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2023/03/14 2.Date of the audit committee approved:2023/03/14 3.Start and end dates of financial reports or unaudited finaicial information of the reporting period:2022/01/01~2022/12/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):5,061,606 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):3,021,115 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):1,227,957 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):1,408,339 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):1,103,0 90 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):1,094,391 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):4.40 11.Total assets end of the period (thousand NTD):9,600,635 12.Total liabilities end of the period (thousand NTD):3,367,354 13.Equity attributable to owners of parent end of the period (thousand NTD):5,658,424 14.Any other matters that need to be specified:None |
||||